OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO)
announces today that the Supervisory Board of the Company
plans to propose Dr. Staf Van Reet as chairman of the
Supervisory Board at the next General Meeting of Shareholders
in May. This appointment will be for a period of four
years.
Dr. Van Reet has a long track record of successes in the
pharma and biotech industry. He served among others as the
Managing Director of Janssen Pharmaceutica N.V. and President
of the Janssen Research Foundation, supervising the worldwide
research and development activities of the Janssen
Pharmaceutica Group (part of the J&J Group of Companies).
Staf also gained extensive experience in the biotech sector
as co-founder of Movetis and Chairman of their Board of
Directors until the acquisition of the company by Shire.
Currently, he is still active in various areas of the life
sciences, among others as Chairman of the Board of Actogenix
and Okapi Sciences and as a regular Board member of
Thrombogenics, Biocartis, TheraSolve and the VIB, the Flemish
Institute of Biotechnology.
The Supervisory Board also announces that Dr. de Ruiter has
informed the Board of her decision to resign from the
Supervisory Board as of January 25.
Hans Stellingsma, chairman of the Supervisory Board of
OctoPlus: "Presently I am serving my third and final term
on OctoPlus' Supervisory Board, which I have chaired since
2005. In view of my other engagements and since we found in
Dr. Staf Van Reet an excellent replacement, I have decided to
step down as chairman at the upcoming shareholders' meeting.
Staf knows the pharmaceutical industry inside out and I
believe his expertise will greatly benefit OctoPlus. We would
like to express our gratitude to Nancy de Ruiter and thank
her for her contribution to the Supervisory Board."
Staf Van Reet, proposed chairman of the Supervisory Board of
OctoPlus: "I feel truly honored being nominated as future
chairman of the Supervisory Board of OctoPlus. The company is
known to me for a long time and I've been impressed by what
it offers to the pharmaceutical and biotech field. OctoPlus
combines an innovative proprietary drug delivery platform
with thorough knowledge of and experience with complex
parenteral drug formulations in general. Moreover, it has a
state of the art infrastructure for development activities as
well as for manufacturing finished clinical trial materials.
I'm excited about the outlook of working together with the
OctoPlus team, its Executive Management and the Supervisory
Board."
Jan Egberts, CEO of OctoPlus: "Personally, I am delighted
with the nomination of Staf Van Reet. Staf's broad scientific
and business experience which he gained during his successful
career at Janssen Pharmaceutica, ultimately culminating in
his role as head of R&D, and in smaller biotech companies
such as Movetis will be a key asset to OctoPlus. I look
forward to work with Staf to further build our business".
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number
+31 (71) 524 1071, or send an e-mail to Investor Relations at
IR@octoplus.nl.
About OctoPlus
OctoPlus is a specialty pharmaceutical company focused on the
development and manufacture of improved injectable
pharmaceuticals based on our proprietary drug delivery
technologies that exhibit fewer side effects, improved
patient convenience and a better efficacy/safety balance than
existing therapies. OctoPlus also focuses on the development
of long-acting, controlled release versions of known protein
therapeutics, peptides and small molecules, including
specialty generics.
The clinically most advanced product incorporating our
technology is Locteron®, a controlled release formulation of
interferon alpha for the treatment of chronic hepatitis C.
OctoPlus licensed Locteron exclusively to Biolex in October
2008. Locteron is being manufactured for Biolex by OctoPlus
and has completed Phase IIb clinical studies with superior
clinical data versus current treatment.
In addition, OctoPlus is a leading European provider of
advanced drug formulation and clinical scale manufacturing
services to the pharmaceutical and biotechnology industries,
with a focus on difficult-to-formulate active pharmaceutical
ingredients.
OctoPlus is listed on NYSE Euronext in Amsterdam under the
symbol OCTO. For more information about OctoPlus, please
visit our website www.octoplus.nl.
This document may contain certain forward-looking
statements relating to the business, financial performance
and results of the Company and the industry in which it
operates. These statements are based on OctoPlus N.V.'s
current plans, estimates and projections, as well as its
expectations of external conditions and events. In particular
the words "expect", "anticipate", "predict", "estimate",
"project", "plan", "may", "should", "would", "will",
"intend", "believe" and similar expressions are intended to
identify forward-looking statements. We caution investors
that a number of important factors, and the inherent risks
and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those
expressed in any forward-looking statements. In the event of
any inconsistency between an English version and a Dutch
version of this document, the English version will prevail
over the Dutch version.
distribué par | Ce noodl a été diffusé par Octoplus NV et initialement mise en ligne sur le site http://www.octoplus.nl. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-25 08:00:03 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |